SCOTUS Spin-Off: Novartis Seeks Preemption for Brand Drugmakers

July 2, 2013
The Novartis v. Fussman liability case pending before the Supreme Court should extend to prescription drugmakers similar preemptive protection from state court-ordered punitive damages as those now afforded generic drug companies, a brief filed by the Washington Legal Foundation argues.
Drug Industry Daily